Martín M, Mahillo E, Llombart-Cussac A, Lluch A, Munarriz B, Pastor M, Alba E, Ruiz A, Antón A, Bermejo B
Hospital Clínico Universitario San Carlos, Madrid, Spain.
Clin Transl Oncol. 2006 Jul;8(7):508-18. doi: 10.1007/s12094-006-0051-7.
The "Alamo" project is a retrospective analysis of 14,854 patients diagnosed of breast cancer between 1990 and 1997 in 50 Spanish hospitals.
Alamo I (AI) consisted of 4,532 patients diagnosed with breast cancer between 1990 and 1993. Data were collected in 2000. Alamo II (AII) consisted of 10,322 patients diagnosed between 1994 and 1997. Data were collected in 2003.
At presentation, there were (AI vs. AII) 17.6% vs. 24.3% at stage I; 55.5% vs. 53.1% at stage II; 18.7% vs. 15% at stage III; 7.2% vs. 5.9 at stage IV. Median age was 57 (AI) vs. 58 years (AII) and 65.9% vs. 67.2% (AI vs. AII) were post-menopausal. Firstline treatment for disease stages I, II and III was surgery in 91% of patients in both studies. Breast conserving surgery rate increased from 20.2% (AI) to 32.7% (AII). Adjuvant systemic treatments were administered to 87.6% (AI) and 92.8% (AII) of patients. Recurrence rate diminished from 36.6% (AI) to 22.5% (AII) and the 9-year survival rate increased from 63.2% (95% CI: 61.5-64.9) to 70.1% (95% CI: 68.5-71.8).
Breast cancer outcomes in Spain have improved from 1990-1993 to 1994-1997, likely because of breast cancer screening program implementation and new therapies.
“阿拉莫”项目是一项对1990年至1997年间在西班牙50家医院确诊的14854例乳腺癌患者进行的回顾性分析。
阿拉莫I（AI）包含1990年至1993年间确诊的4532例乳腺癌患者。数据于2000年收集。阿拉莫II（AII）包含1994年至1997年间确诊的10322例患者。数据于2003年收集。
初诊时，I期患者比例（AI vs. AII）为17.6% vs. 24.3%；II期为55.5% vs. 53.1%；III期为18.7% vs. 15%；IV期为7.2% vs. 5.9%。中位年龄为57岁（AI） vs. 58岁（AII），绝经后患者比例为65.9% vs. 67.2%（AI vs. AII）。两项研究中，I、II和III期疾病的一线治疗在91%的患者中为手术。保乳手术率从20.2%（AI）增至32.7%（AII）。87.6%（AI）和92.8%（AII）的患者接受了辅助性全身治疗。复发率从36.6%（AI）降至22.5%（AII），9年生存率从63.2%（95%CI：61.5 - 64.9）增至70.1%（95%CI：68.5 - 71.8）。
从1990 - 1993年至1994 - 1997年，西班牙乳腺癌的治疗效果有所改善，这可能得益于乳腺癌筛查项目的实施和新疗法的应用。
